DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
About
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Distinctive Features: · This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms. · Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.
The DoW Breast Cancer Transformative Breast Cancer Consortium Development Award is designed for research teams seeking to establish collaborative consortiums that advance breast cancer research and innovation. This development award provides investigators and breast cancer consumer advocates with funding and resources to build consortium frameworks, conduct preliminary research, and prepare comprehensive applications for future full consortium awards. The program is ideal for research institutions, academic medical centers, and collaborative teams committed to addressing critical gaps in breast cancer research identified by the Breast Cancer Research Program (BCRP). Applicants must address at least one of the FY26 BCRP overarching challenges or provide strong justification for alternative approaches. This mechanism emphasizes the integration of consumer advocates as active participants throughout development and execution, ensuring patient perspectives inform research priorities. Teams should apply if they have the scientific expertise, institutional support, and collaborative vision to establish transformative research consortiums that will generate preliminary data and framework documentation necessary for competing in subsequent full consortium funding cycles.
Funding Facts
● Applications openDeadline
July 8, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Amount varies by cycle—consult official program announcement
Deadline
2026-07-08
Grant Type
federal
Application Cycle
Annual (FY26 cycle with July 8, 2026 deadline)
Best For
Research institutions, academic medical centers, and multidisciplinary teams focused on establishing transformative breast cancer research consortiums with consumer advocate participation
Frequently Asked Questions
Who is eligible for DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award?
Specific eligibility criteria are not provided in the available information. Applicants should consult the official FY26 BCRP program announcement and Grants.gov for detailed eligibility requirements, which typically include institutional eligibility, investigator qualifications, and organizational capacity. Note that breast cancer consumer advocates must be active participants in the consortium development process.
How much funding does DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award provide?
The specific funding amount for FY26 has not been disclosed in available materials. Contact the Department of Defense Breast Cancer Research Program or visit the official program website for current funding levels and award ranges.
How do I apply for DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award?
Applications are submitted through established federal grants mechanisms. Visit Grants.gov and search for the FY26 BCRP Transformative Breast Cancer Consortium Development Award announcement for complete application instructions, required forms, and submission deadlines. Note the July 8, 2026 deadline. Applicants should carefully review program guidelines and confirm they are applying to this development award mechanism (not the full consortium award) and that their proposed research addresses FY26 BCRP overarching challenges.
What can DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award funding be used for?
Funding supports consortium development activities including bringing together investigators and breast cancer consumer advocates to establish consortium frameworks and conduct preliminary research. This development phase is designed to generate the foundational work and planning documents necessary for future full consortium award applications. The award provides resources and time for collaborative teams to build infrastructure and collect preliminary data in support of comprehensive future proposals.
Last updated: July 5, 2026